Clinical trials: Type1 Diabetes
Recent Onset type1 Diabetes
A Study of Oral Ladarixin in Recent Onset Type 1 Diabetes and a Low Residual β-cell Function
Objectives The objective of this clinical trial is to assess whether ladarixin treatment has an effect to preserve β-cell function and delay the progression of T1D in adolescent and adult patients.
- Trial name
- NCT04628481
- Testing
- Ladarixin
- Where
- 57 sites in United States, Belgium and 6 more
- Volunteers
- 289 people
- Sponsor
- Dompé Farmaceutici S.p.A
Diabetes type1, Children, Only
Evaluation of the MiniMed 780 System in Paediatric Subjects
The purpose of this study is to demonstrate the safety and performance of the MiniMed™ 780G system in pediatric subjects (2-6 years old) with type 1 diabetes in a home setting.
- Trial name
- LENNY (NCT05574062)
- Testing
- MiniMed 780G Auto Mode with G4S sensor, MiniMed 780G Manual Mode with G4S sensor, MiniMed 780G Auto Mode with DS5 sensor
- Where
- 12 sites in Finland, Italy and 2 more
- Volunteers
- 101 people
- Sponsor
- Medtronic MiniMed, Inc.
Diabetes type1
Evaluation of Satisfaction Regarding Home Healthcare Provider (HHP) Management of Type 1 Diabetic Patients Using a Closed-loop Automatic Insulin Delivery System
SATURN study aims at evaluating Home Healthcare Provider (HHP) Management of type 1 diabetic patients using a closed-loop automatic insulin delivery system (or artificial pancreas), and specifically satisfaction and interactions…
- Trial name
- SATURN (NCT04635280)
- Testing
- any closed-loop automatic insulin delivery system (or artificial pancreas) European Conformity (CE)-marking
- Where
- 2 sites in France
- Volunteers
- 35 people
- Sponsor
- Air Liquide Santé International
Type1 Diabetes Mellitus
Multiple Dose Study to Evaluate the Efficacy, Safety and Pharmacodynamics of REMD-477 in Subjects With Type 1 Diabetes Mellitus
This is a randomized, placebo-controlled, double-blind study to evaluate the efficacy, safety, and pharmacodynamics (PD) of multiple doses of REMD-477 in subjects who have Type 1 diabetes and are currently receiving insulin…
- Trial name
- NCT03117998
- Testing
- REMD-477
- Where
- 11 sites in United States
- Volunteers
- 154 people
- Sponsor
- REMD Biotherapeutics, Inc.
Type1 Diabetes Mellitus
Wharton´s Jelly Derived Mesenchymal Stromal Cell Treatment of Adult Patients Diagnosed With Type I Diabetes
To investigate the safety and tolerance after allogeneic infusion of WJMSCs intravenously in adult patients diagnosed with type 1 diabetes.
- Trial name
- NCT03406585
- Testing
- ProTrans: Allogeneic transplantation with WJMSCs
- Where
- Sweden
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- NextCell Pharma Ab
Diabetes type1
A Study to Assess the Safety and Tolerability of Different Doses of AG019 Administered Alone or in Combination With Teplizumab in Participants With Recent-onset Diagnosed Type 1 Diabetes (T1D)
The purpose of this study is to assess the safety and tolerability of different doses of AG019 administered alone or in combination with teplizumab in participants with recent-onset type 1 diabetes (T1D).
- Trial name
- NCT03751007
- Testing
- AG019 - Low Dose, Teplizumab, AG019 - High Dose
- Where
- 18 sites in United States, Belgium
- Volunteers
- 45 people
- Sponsor
- Precigen Actobio T1D, LLC
Type1 Diabetes Mellitus
A Study to Demonstrate Bioequivalence Between Insulin Glulisine U300 and Insulin Glulisine U100 After a Single Subcutaneous Dose Using the Euglycemic Clamp Technique, in Patients With Type 1 Diabetes Mellitus
Primary Objective: To demonstrate bioequivalence between insulin glulisine given as 300 Units/mL test formulation and insulin glulisine 100 Units/mL reference formulation after a single subcutaneous (SC) dose.
- Trial name
- NCT02910518
- Testing
- Insulin glulisine (U300), Insulin glulisine, Insulin aspart
- Where
- Germany
- Volunteers
- 44 people
- Sponsor
- Sanofi
Type1 Diabetes
Multiple Ascending Dose (MAD) Study of IMT-002 in HLA-DQ8-positive Type 1 Diabetes
This study is designed to characterize the safety, steady-state pharmacokinetics (PK) of IMT-002, and will serve as a dose range identification for the pharmacodynamic effect of blocking self-antigen presentation in adults with…
- Trial name
- NCT04625595
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- Immunomolecular Therapeutics, Inc.
Type1 Diabetes Mellitus
BOL-DP-o-05 as an Add-On Treatment of Subjects With Newly Diagnosed Type 1 Diabetes Mellitus
BOL-DP-o-05 as an Add-On Treatment for Preservation of Beta-Cell Function in Subjects With Newly-Diagnosed Type 1 Diabetes Mellitus (T1DM)
- Trial name
- NCT04102202
- Testing
- BOL-DP-o-05
- Sponsor
- Breath of Life International Pharma Ltd
Type1 Diabetes Mellitus
A Study of LY900014 in a Medtronic Pump
The purpose of this study is to compare the study drug LY900014 to insulin lispro (Humalog) when both are delivered by the Medtronic MiniMed 670G System in adults with type 1 diabetes (T1D).
- Trial name
- NCT03760640
- Testing
- LY900014, Insulin Lispro
- Where
- 2 sites in United States
- Volunteers
- 42 people
- Sponsor
- Eli Lilly and Company
Type1 Diabetes Mellitus
Insulet Artificial Pancreas Free-Living IDE3
Subjects will undergo a 7±1 day outpatient, standard therapy phase during which sensor and insulin data will be collected. Subjects or their caregivers will manage their diabetes at home per their usual routine using the study…
- Trial name
- NCT03216460
- Testing
- Insulet automated glucose control system
- Where
- 3 sites in United States
- Volunteers
- 120 people
- Sponsor
- Insulet Corporation
Type1 Diabetes Mellitus
21 Day Comparison of Continuous Insulin Infusion Using HDV Insulin to Standard Insulin in Type 1 Diabetes Mellitus
Single Center, Double Blind, Active Comparator Controlled 2-Way Crossover Multiple Dose Safety, Tolerability and Efficacy Study
- Trial name
- NCT03156361
- Testing
- HDV insulin lispro 100 UNIT/mL, Insulin Lispro 100 Units/mL
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Diasome Pharmaceuticals
Type1 Diabetes Mellitus
A Study of an Automated Insulin Delivery System in Participants With Type 1 Diabetes Mellitus (T1DM)
The Automated Insulin Delivery (AID) System is an investigational insulin delivery device being developed for use for participants with diabetes.
- Trial name
- NCT03367390
- Testing
- AID System, Insulin Lispro
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Eli Lilly and Company
Type1 Diabetes Mellitus
A Trial to Evaluate the Pharmacokinetic and Pharmacodynamic Properties of BioChaperone® Insulin Lispro, Fiasp® and NovoRapid® Delivered by an Insulin Pump
This is a single-centre, randomised, double-blind, three-period, complete cross-over trial comparing the pharmacokinetic and the pharmacodynamic properties of BioChaperone® insulin lispro and the two active comparators Fiasp® and…
- Trial name
- NCT03179332
- Testing
- BioChaperone® insulin lispro, Fiasp®, Novorapid®
- Where
- Germany
- Volunteers
- 43 people
- Sponsor
- Adocia
Type1 Diabetes Mellitus, Type2 Diabetes Mellitus
Multiple Ascending Dose Study of HM12470 in Type 1 and Type 2 Diabetes Mellitus
This is a phase 1 multiple ascending dose (MAD) study, conducted in subjects with Type 1 and Type 2 diabetes mellitus
- Trial name
- NCT03332849
- Testing
- HM12470
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Type1 Diabetes
Euglycemic Clamp Study Comparing Two New Insulin Glargine Formulations in Subjects With Type 1 Diabetes Mellitus
Primary Objective: To demonstrate equivalence in exposure to insulin glargine given as test formulation T and reference formulation R in steady state conditions after 6 once-daily subcutaneous (SC) doses Secondary Objective: To…
- Trial name
- NCT01838083
- Testing
- Insulin glargine new formulation HOE901
- Where
- Germany
- Volunteers
- 50 people
- Sponsor
- Sanofi
Type1 Diabetes
Comparative Glucose Clamp Study of Wockhardt's Recombinant Insulin Analog Glargine(Glaritus) With Lantus in T1DM
The aim of this trial is to demonstrate bioequivalence of Glaritus® to Lantus® with regard to its total and to its maximum serum insulin concentrations.
- Trial name
- NCT01357603
- Testing
- Glargine
- Where
- United States
- Volunteers
- 111 people
- Sponsor
- Wockhardt